Neuroprotective FK506 Does Not Alter In Vivo Nitric Oxide Production During Ischemia and Early Reperfusion in Rats | Zendy

Thomas J. K. Toung | Zendy; Anish Bhardwaj | Zendy; Valina L. Dawson | Zendy; Ted M. Dawson | Zendy; Richard J. Traystman | Zendy; Patricia D. Hurn | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Neuroprotective FK506 Does Not Alter In Vivo Nitric Oxide Production During Ischemia and Early Reperfusion in Rats

Author(s) -

Thomas J. K. Toung,

Anish Bhardwaj,

Valina L. Dawson,

Ted M. Dawson,

Richard J. Traystman,

Patricia D. Hurn

Publication year - 1999

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/01.str.30.6.1279

Subject(s) - medicine , neuroprotection , anesthesia , microdialysis , ischemia , nitric oxide , nitric oxide synthase , reperfusion injury , in vivo , infarction , saline , pharmacology , central nervous system , myocardial infarction , biology , microbiology and biotechnology

Previous studies have demonstrated that the immunosuppressant FK506 provides neuroprotection in experimental brain injury and suggest that this action may be mediated by suppression of neuronal nitric oxide synthase activation that occurs after ischemic depolarization. We sought to determine whether FK506 reduces histological injury after middle cerebral artery occlusion (MCAO) in the rat and whether the neuroprotective effect is mediated via suppression of in vivo nitric oxide (NO) production during ischemia or early reperfusion.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research